Quarterly Activities/Appendix 4C Cash Flow Report

Melbourne, Australia & Dallas, United States – January 28, 2026 – Epiminder Limited (ASX: EPI) (“Epiminder” or “the Company”) , a pioneer medical device company developing breakthrough epilepsy monitoring technology, is pleased to release its inaugural Appendix 4C and a quarterly update for the period to 31 December 2025 (“Q2 FY26”) for the Company and its subsidiaries. Key Highlights for Q2 FY26